Researchers claim that COVID-19 patients in a clinical trial are responding quickly to Remdesivir, a finding which they said is "promising," while also emphasising the need for more trials to test the effectiveness of the antiviral drug.
According to the researchers from the Houston Methodist Hospital in Texas, US, the trial's criteria allows for the treatment of patients early in their clinical course, and in some cases when they may have otherwise been intubated. "Early results are promising, and that is important right now.
Much of what we are learning about COVID-19 management is centred around preventing quick deterioration," said Katherine K. Perez, an infectious diseases pharmacist from Houston Methodist Hospital in the US. "Timing